F-AraG
Phase 2Small molecule
F-AraG is one of 170 small molecule programs targeting Lymphoma. It is currently in Phase 2.
5
Indications
11
Total Trials
5
Active Trials
169
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Spikevax
ModernaPreclinical
F-AraG
CCellSight Technologies, Inc.
Phase 2
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Imaging2 trials
Radiation Therapy1 trial
Patients With Solid Tumors1 trial
5 more indications
Lymphoma1 trial
Advanced NSCLC1 trial
Small Cell Lung Cancer1 trial
Non-Small Cell Lung Cancer1 trial
PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04524195·4 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-AraG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCellSight Technologies, Inc.